Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Measuring Heart Chamber Pressure Around a Combined Atrial Fibrillation Procedure

Observes heart pressure changes in adults with atrial fibrillation undergoing a combined heart procedure.

Plain-language title generated from the registry record
Registry title: The Impact of Atrial Pressure Change Before and After Combined Procedure

Key facts

Where
Shanghai, ChinaSee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with atrial fibrillation who are having catheter ablation together with left atrial appendage closure in one procedure. It measures pressure in the heart's upper chambers before and after.

Age
Over 18 years
Sex
All sexes
Disease stage
Atrial fibrillation recorded by 12-lead ECG or Holter lasting longer than 30 seconds within the last 6 months. Also at least one of: high stroke risk (CHA2DS2-VASc score 3 or more in women, 2 or more in men) and/or high bleeding risk (HAS-BLED score 3 or more); cannot take oral anticoagulation (OAC); or refused OAC after being fully informed.
Earlier treatment
No previous atrial fibrillation surgery (MAZE) or catheter ablation, no previous cardiac surgery (valve replacement, septal repair), and no previous atrioventricular node ablation.

Main reasons for not taking part

  • Reversible causes of atrial fibrillation (thyroid disorders, recent major surgery, trauma, acute alcohol intoxication)
  • Other arrhythmia such as atrial flutter or ventricular tachycardia
  • Major heart disease within 3 months (acute heart attack, ventricular fibrillation) or congenital heart disease
  • Life expectancy under 1 year
  • Women who could become pregnant

Read by machine on 12 November 2026.

Where in China

  • Department of Cardiology, Shanghai Tenth People's HospitalShanghai, ChinaContact: Zhongyuan Ren, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Shanghai 10th People's Hospital
Trial code
NCT05106270
Record updated
2 September 2022
Original description
One-stop procedure combining catheter ablation (CA) and left atrial appendage closure (LAAC) has been a feasible treatment for patients with atrial fibrillation at high risk of stroke and/or bleeding. Although it could achieve considerable rhythm control and stroke prophylaxis, a number of patients has experienced progressive heart failure after the procedure. Notably, previous studies indicate that both pulmonary vein isolation by CA and LAAC could significantly increase left atrial pressure, while currently no study has investigated left atrial pressure change in patients underwent combined procedure. The investigators hypothesise that combined procedure would significantly increase left atrial pressure and subsequently deteriorate cardiac function. Therefore, the investigators aim to measure the left and right atrial pressure change before and after CA and LAAC in combined procedure, and investigate the influence of the pressure change on clinical outcomes.Read full original descriptionShow less

The Impact of Atrial Pressure Change Before and After One-stop Procedure Combining Catheter Ablation and Left Atrial Appendage Closure on the Prognosis of Patients With Atrial Fibrillation

One-stop procedure combining catheter ablation (CA) and left atrial appendage closure (LAAC) has been a feasible treatment for patients with atrial fibrillation at high risk of stroke and/or bleeding. Although it could achieve considerable rhythm control and stroke prophylaxis, a number of patients has experienced progressive heart failure after the procedure. Notably, previous studies indicate that both pulmonary vein isolation by CA and LAAC could significantly increase left atrial pressure, while currently no study has investigated left atrial pressure change in patients underwent combined procedure. The investigators hypothesise that combined procedure would significantly increase left atrial pressure and subsequently deteriorate cardiac function. Therefore, the investigators aim to measure the left and right atrial pressure change before and after CA and LAAC in combined procedure, and investigate the influence of the pressure change on clinical outcomes.

Inclusion: Atrial fibrillation recorded by 12-lead ECG or Holter that last for longer than 30 seconds within the preceding 6 months; Eligible for left atrial appendage closure, that meet at least one of the followings:; At high risk of stroke (CHA2DS2-VASc score≥3 in female, ≥2 in male) and/or bleeding (HAS-BLED score≥3); Contraindicated to oral anticoagulation (OAC); Refused OAC treatment albeit comprehensively informed of the necessity and benefits of OAC treatment; Capable of understanding and signing the informed consent form; Aged over 18 years.

Exclusion: Concomitant arrhythmia including atrial flutter, ventricular tachycardia; A previous history of atrial fibrillation surgery (MAZE surgery) or catheter ablation; A previous history of cardiac surgery including any valvular replacement, septal repair; A previous history of atrioventricular node ablation; Reversible causes of atrial fibrillation, including thyroid disorders, recent major surgery, trauma, acute alcoholic intoxication; A recent history of major cardiovascular disease within 3 months, including acute myocardial infarction, ventricular fibrillation; A history of congenital heart disease; A history of lobectomy due to any medical condition; Complicated by other diseases with life expectation <1 year; Women with childbearing potential; Participated in other interventional clinical trials that might affect prognosis; Unable to understand or give informed consent form.

ClinicalTrials.gov NCT05106270